GSK licenses Hutchmed's KRAS-EGFR antibody-drug conjugate for $110 million upfront

GSK announced it will pay $110 million upfront to obtain a license for a KRAS-EGFR antibody-drug conjugate developed by Chinese biopharma Hutchmed. The agreement also includes potential milestone payments that could total up to $1.185 billion if development and commercial targets are met.

The licensed candidate combines KRAS and EGFR targeting mechanisms, aiming to address cancers driven by these pathways. GSK said the deal fits its strategy to broaden its oncology portfolio with innovative therapies.

For Hutchmed, the upfront cash provides immediate funding while the milestone structure offers significant upside as the program advances. The partnership highlights growing collaboration between Western and Chinese drug developers.